DK1295611T3 - Oligonukleotid-transformerende forbindelser - Google Patents
Oligonukleotid-transformerende forbindelserInfo
- Publication number
- DK1295611T3 DK1295611T3 DK01938732.3T DK01938732T DK1295611T3 DK 1295611 T3 DK1295611 T3 DK 1295611T3 DK 01938732 T DK01938732 T DK 01938732T DK 1295611 T3 DK1295611 T3 DK 1295611T3
- Authority
- DK
- Denmark
- Prior art keywords
- oligonucleotide
- transforming compounds
- transforming
- compounds
- collagen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000184502 | 2000-06-20 | ||
PCT/JP2001/005195 WO2001097857A1 (fr) | 2000-06-20 | 2001-06-19 | Preparations destinees au transfert d'oligonucleotides |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1295611T3 true DK1295611T3 (da) | 2010-10-04 |
Family
ID=18684937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01938732.3T DK1295611T3 (da) | 2000-06-20 | 2001-06-19 | Oligonukleotid-transformerende forbindelser |
Country Status (10)
Country | Link |
---|---|
US (3) | US20040052840A1 (da) |
EP (1) | EP1295611B1 (da) |
JP (1) | JP5118285B2 (da) |
AT (1) | ATE478688T1 (da) |
AU (1) | AU2001264317A1 (da) |
DE (1) | DE60142899D1 (da) |
DK (1) | DK1295611T3 (da) |
ES (1) | ES2349137T3 (da) |
PT (1) | PT1295611E (da) |
WO (1) | WO2001097857A1 (da) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW586934B (en) * | 1997-05-19 | 2004-05-11 | Sumitomo Pharma | Immunopotentiating composition |
ES2349137T3 (es) * | 2000-06-20 | 2010-12-28 | Dainippon Sumitomo Pharma Co., Ltd. | Preparación para transferir oligonucleótidos. |
DK1407787T3 (da) | 2001-06-20 | 2009-06-02 | Dainippon Sumitomo Pharma Co | Fremgangsmåde til fremme af nukleinsyreoverförsel |
US20100104631A1 (en) * | 2001-08-13 | 2010-04-29 | Lipella Pharmaceuticals Inc. | Method of treatment for bladder dysfunction |
AU2003264507A1 (en) * | 2002-09-20 | 2004-04-08 | Koken Co., Ltd. | Site-specific gene conversion promoter and gene therapeutic |
US20080318319A1 (en) * | 2003-12-19 | 2008-12-25 | Yoshiko Minakuchi | Novel Method of Nucleic Acid Transfer |
US20090062184A1 (en) * | 2005-03-24 | 2009-03-05 | Dainippon Sumitomo Pharma Co., Ltd. | Fine particulate preparation comprising complex of nucleic acid molecule and collagen |
US7838502B2 (en) * | 2005-05-06 | 2010-11-23 | University Of Massachusetts Medical School | Compositions and methods to modulate H. influenzae pathogenesis |
WO2006126600A1 (ja) * | 2005-05-25 | 2006-11-30 | National University Corporation Nagoya Universtiy | 血管閉塞性疾患用医薬組成物 |
KR100777249B1 (ko) * | 2006-02-14 | 2007-11-28 | (주)바이오니아 | 건조 올리고뉴클레오티드 조성물 및 이의 제조 방법 |
US20100166739A1 (en) * | 2008-12-30 | 2010-07-01 | Lipella Paharmaceuticals Inc. | Methods and Compositions for Diagnosing Urological Disorders |
FR3066115B1 (fr) * | 2017-05-10 | 2019-06-28 | Universite de Bordeaux | Comprimes de vecteurs d'acides nucleiques |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5115094B2 (da) * | 1972-11-01 | 1976-05-14 | ||
US5069936A (en) * | 1987-06-25 | 1991-12-03 | Yen Richard C K | Manufacturing protein microspheres |
US5078997A (en) * | 1988-07-13 | 1992-01-07 | Cetus Corporation | Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers |
US5098890A (en) * | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
US5614587A (en) * | 1988-11-21 | 1997-03-25 | Collagen Corporation | Collagen-based bioadhesive compositions |
US5936035A (en) * | 1988-11-21 | 1999-08-10 | Cohesion Technologies, Inc. | Biocompatible adhesive compositions |
JP3187410B2 (ja) * | 1989-08-10 | 2001-07-11 | 住友製薬株式会社 | 脳内投与用徐放性製剤 |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
FR2694895B1 (fr) * | 1992-08-20 | 1994-11-10 | Coletica | Procédé de fabrication de microparticules en émulsion par modification de la composition chimique de la phase dispersée après émulsification. |
US5646042A (en) * | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
ATE182336T1 (de) * | 1993-05-28 | 1999-08-15 | Chiron Corp | Peptidinhibitoren der urokinaserezeptor-aktivität |
HUT74509A (en) * | 1993-09-09 | 1997-01-28 | Schering Ag | Active principles and gas containing microparticles, their use for realising active principles in ultrasonically controlled manner, and process for preparing them |
CA2140053C (en) * | 1994-02-09 | 2000-04-04 | Joel S. Rosenblatt | Collagen-based injectable drug delivery system and its use |
US5942496A (en) * | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
US5583034A (en) * | 1994-02-22 | 1996-12-10 | La Jolla Institute For Allergy And Immunology | Enhancement of adoptosis using antisense oligonucleotides |
US5844107A (en) * | 1994-03-23 | 1998-12-01 | Case Western Reserve University | Compacted nucleic acids and their delivery to cells |
US5563255A (en) * | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
CA2193954A1 (en) * | 1994-06-27 | 1996-01-04 | Vu L. Truong | Targeted gene delivery system |
US6998268B2 (en) * | 1995-07-03 | 2006-02-14 | Dainippon Sumitomo Pharma Co. Ltd. | Gene preparations |
JP3867160B2 (ja) * | 1995-07-03 | 2007-01-10 | 大日本住友製薬株式会社 | 遺伝子製剤 |
ES2293648T3 (es) * | 1995-07-03 | 2008-03-16 | Koken Co., Ltd. | Preparaciones de genes que contienen atelocolageno. |
JP2000507915A (ja) * | 1995-10-23 | 2000-06-27 | ハイアル・ファーマシューティカル・オーストラリア・リミテッド | 遺伝子療法のためのdna担体としてのヒアルロン酸および異常な網膜血管新生を治療するためのvegfアンチセンスdna |
CA2239775C (en) * | 1995-12-18 | 2008-07-15 | Collagen Corporation | Crosslinked polymer compositions and methods for their use |
AU728146B2 (en) * | 1996-03-14 | 2001-01-04 | Immune Response Corporation, The | Targeted delivery of genes encoding interferon |
US6133437A (en) * | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
US5874006A (en) * | 1996-10-31 | 1999-02-23 | Matrix Pharmaceutical, Inc. | Aseptic collagen concentration process |
US6042820A (en) * | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
US6218112B1 (en) * | 1996-12-23 | 2001-04-17 | Cobra Therapeutics Limited | Optimization of gene delivery and gene delivery system |
WO1998030575A1 (en) * | 1997-01-08 | 1998-07-16 | Proligo Llc | Bioconjugation of macromolecules |
US6524613B1 (en) * | 1997-04-30 | 2003-02-25 | Regents Of The University Of Minnesota | Hepatocellular chimeraplasty |
AU2868099A (en) * | 1998-02-13 | 1999-08-30 | Selective Genetics, Inc. | Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby |
JP4424850B2 (ja) * | 1998-05-22 | 2010-03-03 | 大日本住友製薬株式会社 | 安定な遺伝子製剤 |
AU2001251115A1 (en) * | 2000-03-31 | 2001-10-15 | Trustees Of Boston University | Use of locally applied dna fragments |
ES2349137T3 (es) * | 2000-06-20 | 2010-12-28 | Dainippon Sumitomo Pharma Co., Ltd. | Preparación para transferir oligonucleótidos. |
JP2002325572A (ja) * | 2000-12-25 | 2002-11-12 | Univ Osaka | 外来物質の導入方法 |
DK1407787T3 (da) * | 2001-06-20 | 2009-06-02 | Dainippon Sumitomo Pharma Co | Fremgangsmåde til fremme af nukleinsyreoverförsel |
US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
US20060030534A1 (en) * | 2002-09-04 | 2006-02-09 | Gabriele Dorn | Treatment of neurological disorders by dsrna administration |
AU2003264507A1 (en) * | 2002-09-20 | 2004-04-08 | Koken Co., Ltd. | Site-specific gene conversion promoter and gene therapeutic |
EP1562970A4 (en) * | 2002-11-01 | 2006-04-12 | Univ Pennsylvania | COMPOSITIONS AND METHODS FOR INHIBITING HIF-1 ALPHA WITH ARNS |
EP2251434B1 (en) * | 2003-01-16 | 2014-07-30 | The Trustees of The University of Pennsylvania | Compositions and methods for siRNA inhibition of ICAM-1 |
US8227434B1 (en) * | 2003-11-04 | 2012-07-24 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Materials and methods for treating oncological disorders |
ES2523147T3 (es) * | 2004-02-26 | 2014-11-21 | Baylor Research Institute | Composiciones y métodos para el tratamiento sistémico de la artritis |
JP4991547B2 (ja) * | 2004-09-28 | 2012-08-01 | クアーク・ファーマスーティカルス、インコーポレイテッド | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
JP2008516993A (ja) * | 2004-10-22 | 2008-05-22 | ユニベルシテ ラバル | 疼痛の治療および予防における神経膠細胞由来bdnfの調節 |
US7585848B2 (en) * | 2005-01-11 | 2009-09-08 | Rush University Medical Center | Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc |
WO2007082899A1 (en) * | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
EP2047864B1 (en) * | 2006-06-16 | 2017-04-05 | Taisho Pharmaceutical Co., Ltd. | Use of rpn2 gene expression inhibitor |
CA2658550C (en) * | 2006-07-21 | 2018-06-19 | Silence Therapeutics Ag | Means for inhibiting the expression of protein kinase 3 |
US7825101B2 (en) * | 2006-08-30 | 2010-11-02 | The Board Of Trustees Of The University Of Illinois | Modulation of MLCK-L expression and uses thereof |
WO2008041933A2 (en) * | 2006-10-02 | 2008-04-10 | Aprea Ab | Rna interference against wrap53 to treat hyperproliferative diseases |
US7812002B2 (en) * | 2007-03-21 | 2010-10-12 | Quark Pharmaceuticals, Inc. | Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer |
CA2782728A1 (en) * | 2009-12-04 | 2011-06-09 | Opko Ophthalmics, Llc | Compositions and methods for inhibition of vegf |
-
2001
- 2001-06-19 ES ES01938732T patent/ES2349137T3/es not_active Expired - Lifetime
- 2001-06-19 EP EP01938732A patent/EP1295611B1/en not_active Expired - Lifetime
- 2001-06-19 DE DE60142899T patent/DE60142899D1/de not_active Expired - Lifetime
- 2001-06-19 JP JP2002503340A patent/JP5118285B2/ja not_active Expired - Fee Related
- 2001-06-19 WO PCT/JP2001/005195 patent/WO2001097857A1/ja active Application Filing
- 2001-06-19 US US10/311,621 patent/US20040052840A1/en not_active Abandoned
- 2001-06-19 AT AT01938732T patent/ATE478688T1/de active
- 2001-06-19 PT PT01938732T patent/PT1295611E/pt unknown
- 2001-06-19 AU AU2001264317A patent/AU2001264317A1/en not_active Abandoned
- 2001-06-19 DK DK01938732.3T patent/DK1295611T3/da active
-
2009
- 2009-06-17 US US12/486,703 patent/US20090258933A1/en not_active Abandoned
-
2010
- 2010-10-13 US US12/904,054 patent/US20110028535A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1295611B1 (en) | 2010-08-25 |
EP1295611A1 (en) | 2003-03-26 |
JP5118285B2 (ja) | 2013-01-16 |
EP1295611A4 (en) | 2009-07-08 |
US20110028535A1 (en) | 2011-02-03 |
ATE478688T1 (de) | 2010-09-15 |
ES2349137T3 (es) | 2010-12-28 |
US20090258933A1 (en) | 2009-10-15 |
PT1295611E (pt) | 2010-09-14 |
US20040052840A1 (en) | 2004-03-18 |
AU2001264317A1 (en) | 2002-01-02 |
DE60142899D1 (de) | 2010-10-07 |
WO2001097857A1 (fr) | 2001-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1459751E (pt) | (s,s)-reboxetina para tratar as enxaquecas | |
EP1190099A4 (en) | ANTISENSE MODULATION OF THE P13K P85 EXPRESSION | |
WO2002036743A3 (en) | Antisense modulation of calreticulin expression | |
ATE263354T1 (de) | Vorrichtung zur herstellung von kontaktkörpern | |
EP1325019A4 (en) | ANTISENSE MODULATION OF CLUSTERIN EXPRESSION | |
AP2210A (en) | 4-tetrazolyl-4phenylpiperidine derivatives for treating pain. | |
EP1248794A4 (en) | ANTISENSE MODULATION OF SMAD7 PROTEIN EXPRESSION | |
DK1295611T3 (da) | Oligonukleotid-transformerende forbindelser | |
WO2001029175A3 (en) | Antisense modulation of fra-1 expression | |
AU2180501A (en) | Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide | |
WO2004010956A3 (en) | Antisense modulation of lar expression | |
EP1235924A4 (en) | ANTISENSE MODULATION OF KAPPA B NUCLEAR FACTOR RECEPTOR ACTIVATOR (RANK) EXPRESSION | |
WO2003027229A3 (en) | Antisense modulation of rip2 expression | |
ES1044983Y (es) | Aparato de termoestimulacion para tratamientos terapeuticos. | |
WO2003044167A3 (en) | Antisense modulation of human fxr expression | |
EP1642884A4 (en) | PROCESS FOR PREPARING OPTICALLY ACTIVE 1-ALKYL SUBSTITUTED 2,2,2-TRIFLUORETHYLAMINE | |
WO2002041836A3 (en) | Antisense modulation of src-1 expression | |
WO2004001061A3 (en) | Antisense modulation of heme oxygenase 1 expression | |
IT1311624B1 (it) | Apparato per il trattamento di piantagioni in filari. | |
WO2003033659A3 (en) | Antisense modulation of matrix metalloproteinase 1 expression | |
ES1045858Y (es) | Maquina para tratamiento de aceitunas. | |
WO2002040637A3 (en) | Antisense modulation of pi3k p85 expression | |
WO2003031576A3 (en) | Antisense modulation of inhibitor-kappa b kinase-gamma expression | |
WO2002055535A3 (en) | Antisense modulation of cytohesin-1 expression | |
WO2004015126A3 (en) | Antisense modulation of edg1 expression |